New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
08:10 EDTTROVTrovagene presents urine-based HPV assay clinical results
Trovagene announced that results from two independent clinical studies were presented at the 29th International Papillomavirus Conference. Results from both pilot studies consistently demonstrated that the company's urine-based assay for the detection of high-risk HPV had high sensitivity for identifying women with high grade cervical intraepithelial neoplasia. Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing. In an oral presentation entitled "Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," results from a population-based National Cancer Institute study, conducted at the University of Oklahoma Health Sciences Center, were released. A second presentation entitled "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women" included results from a study conducted at University of North Carolina, Chapel Hill. The company said, "The positive study results presented at the IPV Conference are very encouraging as we continue to conduct clinical studies to evaluate the performance of our urine-based high-risk HPV assay as a viable alternative to conventional HPV testing from a cervical specimen. A significantly larger, blinded study which compares sensitivity of detecting high-risk HPV in patients with CIN2/3 in urine versus cervical samples is ongoing and results will be reported by 1Q15."
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:52 EDTTROVTrovagene price target raised to $13 from $10 at Maxim
Maxim raised Buy rated Trovagene's price target to $13 following the presentation at the 2015 European Lung Cancer Conference demonstrating high clinical utility of its Precision Cancer platform.
April 17, 2015
12:21 EDTTROVOn The Fly: Top stock stories at midday
Subscribe for More Information
10:31 EDTTROVTrovagene says ctDNA assay outperformed tissue biopsy in clinical study
Trovagene announced that clinical data presented at the 2015 European Lung Cancer Conference demonstrate that its urine-based Precision Cancer Monitoring platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland. In an interim analysis of 34 patients from an ongoing clinical study, Trovagene's PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The company's urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. Trovagene's PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use